Cytarabine

Generic Name: Cytarabine

Brand Names: Cytosar, Vyxeos

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₃N_₃O_₅

CAS Number: 147-94-4

Unique Ingredient Identifier: 04079A1RDZ

Background: A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

Indication: For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.

Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia

Associated Therapies: -

Clinical Trials

High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic Malignancies

Phase 1

Completed

Conditions: Drug/Agent Toxicity by Tissue/Organ
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2004-04-22

Last Posted Date: 2015-12-14

Lead Sponsor: Virginia Commonwealth University

Target Recruit Count: 15

Registration Number: NCT00002818

Locations: 🇺🇸
Massey Cancer Center, Richmond, Virginia, United States

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Acute Myeloid Leukemia in Second Remission

Phase 2

Completed

Conditions: Leukemia

Interventions: Biological: filgrastim
Drug: busulfan
Drug: cytarabine
Drug: etoposide
Drug: methotrexate
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2004-04-22

Last Posted Date: 2016-06-28

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 51

Registration Number: NCT00002768

Locations: 🇺🇸
UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States
🇺🇸
Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
🇺🇸
St. Joseph's Hospital and Medical Center, Paterson, New Jersey, United States

Radiolabeled Monoclonal Antibody, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory B-Cell Cancer

Phase 1

Conditions: Lymphoma
Leukemia

First Posted Date: 2004-04-15

Last Posted Date: 2009-06-09

Lead Sponsor: Garden State Cancer Center at the Center for Molecular Medicine and Immunology

Registration Number: NCT00004086

Locations: 🇺🇸
Garden State Cancer Center, Belleville, New Jersey, United States

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Primary CNS Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2004-04-14

Last Posted Date: 2012-07-02

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 50

Registration Number: NCT00003061

Locations: 🇧🇪
U.Z. Gasthuisberg, Leuven, Belgium
🇫🇷
Institut Gustave Roussy, Villejuif, France
🇳🇱
Rotterdam Cancer Institute, Rotterdam, Netherlands

and more 4 locations

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia

Phase 3

Conditions: Leukemia

First Posted Date: 2004-04-13

Last Posted Date: 2013-11-06

Lead Sponsor: Facet Biotech

Registration Number: NCT00006045

Locations: 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇳🇱
Academisch Medisch Centrum, Amsterdam, Netherlands

and more 56 locations

T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies

Phase 1

Completed

Conditions: Chronic Myeloproliferative Disorders
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms

First Posted Date: 2004-04-08

Last Posted Date: 2012-03-08

Lead Sponsor: National Institutes of Health Clinical Center (CC)

Target Recruit Count: 20

Registration Number: NCT00080925

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States

Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: rituximab
Drug: carmustine
Drug: cytarabine
Drug: etoposide
Drug: melphalan
Procedure: autologous bone marrow transplantation
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2004-04-08

Last Posted Date: 2023-10-06

Lead Sponsor: University of Nebraska

Target Recruit Count: 68

Registration Number: NCT00080886

Locations: 🇺🇸
University of Nebraska Medical Center, Eppley Cancer Center, Omaha, Nebraska, United States

Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia

Phase 2

Completed

Conditions: Leukemia
Lymphoma

Interventions: Drug: cyclophosphamide
Drug: cytarabine
Drug: dexamethasone
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: ifosfamide
Drug: leucovorin calcium
Drug: mesna
Drug: methotrexate
Drug: prednisone
Drug: therapeutic hydrocortisone
Drug: vincristine sulfate
Radiation: low-LET cobalt-60 gamma ray therapy
Radiation: low-LET photon therapy

First Posted Date: 2004-04-06

Last Posted Date: 2016-07-04

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 134

Registration Number: NCT00002494

Locations: 🇺🇸
Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
🇺🇸
University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States
🇺🇸
Ellis Fischel Cancer Center - Columbia, Columbia, Missouri, United States

and more 20 locations

Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Phase 3

Completed

Conditions: Lymphoma

Interventions: Biological: rituximab
Drug: cisplatin
Drug: cytarabine
Drug: dexamethasone
Drug: gemcitabine hydrochloride

First Posted Date: 2004-03-09

Last Posted Date: 2023-08-23

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 849

Registration Number: NCT00078949

Locations: 🇨🇦
Allan Blair Cancer Centre, Regina, Saskatchewan, Canada
🇺🇸
Indiana University Medical Center, Indianapolis, Indiana, United States
🇺🇸
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States

and more 24 locations

Radiation Therapy to the Head or Intrathecal Chemotherapy Plus High Dose Cytarabine in Preventing CNS Disease in Children With Acute Lymphoblastic Leukemia

Phase 3

Withdrawn

Conditions: Leukemia

First Posted Date: 2004-02-27

Last Posted Date: 2012-03-23

Lead Sponsor: National Institutes of Health Clinical Center (CC)

Registration Number: NCT00019409

Locations: 🇮🇳
Tata Memorial Centre, Mumbai, India
🇮🇳
Cancer Institute (W.I.A.), Madras, India
🇮🇳
All-India Institute of Medical Sciences, New Delhi, India

and more 3 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy